Dabur Pharma gets US nod for carboplatin

New Delhi, Oct 3 (UNI) Drug major Dabur Pharma today said its wholly-owned subsidiary Dabur Oncology Plc, UK, has got the US Food and Drug Administration (FDA) approval for its anti-cancer drug carboplatin.

''Dabur Oncology Plc, UK, has been granted Abbreviated New Drug Application (ANDA) approval for its drug carboplatin,'' a company statement said.

Dabur Pharma Ltd is a leading Indian company for cancer research and anticancer products. The company also markets a range of products in the cardiovascular, antibacterial, antidiabetic and digestive segments.

It operates in Europe and in some other markets through its fully-owned subsidiary Dabur Oncology Plc.

UNI SRS PV DS1303